Author:
Chen Delphine L.,Cheriyan Joseph,Chilvers Edwin R.,Choudhury Gourab,Coello Christopher,Connell Martin,Fisk Marie,Groves Ashley M.,Gunn Roger N.,Holman Beverley F.,Hutton Brian F.,Lee Sarah,MacNee William,Mohan Divya,Parr David,Subramanian Deepak,Tal-Singer Ruth,Thielemans Kris,van Beek Edwin J.R.,Vass Laurence,Wellen Jeremy W.,Wilkinson Ian,Wilson Frederick J.
Publisher
Society of Nuclear Medicine
Subject
Radiology, Nuclear Medicine and imaging
Reference64 articles.
1. The future of chronic obstructive pulmonary disease treatment—difficulties of and barriers to drug development
2. Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Institutes of Health; National Heart, Lung, and Blood Institute; 2012.
3. Phase III and submission failures: 2007–2010
4. Estimating The Cost Of New Drug Development: Is It Really $802 Million?
5. Biomarker qualification program. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm. U.S. Food and Drug Administration website. Accessed January 11, 2017.
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献